These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Methods of estimation of IC50 and SC50 parameters for indirect response models from single dose data. Wyska E; Mager DE; Krzyzanski W J Pharm Sci; 2003 Jul; 92(7):1438-54. PubMed ID: 12820148 [TBL] [Abstract][Full Text] [Related]
9. A theory of drug tolerance and dependence II: the mathematical model. Peper A J Theor Biol; 2004 Aug; 229(4):491-500. PubMed ID: 15246786 [TBL] [Abstract][Full Text] [Related]
10. Intermittent adaptation. A theory of drug tolerance, dependence and addiction. Peper A Pharmacopsychiatry; 2009 May; 42 Suppl 1():S129-43. PubMed ID: 19434551 [TBL] [Abstract][Full Text] [Related]
11. Long-lasting rebound cue effects following single doses of nicotine and amphetamine: implications for understanding tolerance. Barrett RJ; Caul WF; Stadler JR; Smith RL Psychopharmacology (Berl); 2001 Oct; 157(4):349-57. PubMed ID: 11605093 [TBL] [Abstract][Full Text] [Related]
12. Assessment of basic indirect pharmacodynamic response models with physiological limits. Yao Z; Krzyzanski W; Jusko WJ J Pharmacokinet Pharmacodyn; 2006 Apr; 33(2):167-93. PubMed ID: 16547797 [TBL] [Abstract][Full Text] [Related]
13. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Andes D; Craig WA Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987 [TBL] [Abstract][Full Text] [Related]
14. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232 [TBL] [Abstract][Full Text] [Related]
15. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. Gardner SN Cancer Res; 2000 Mar; 60(5):1417-25. PubMed ID: 10728708 [TBL] [Abstract][Full Text] [Related]
16. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. Meibohm B; Derendorf H Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388 [TBL] [Abstract][Full Text] [Related]
17. Choice of number of doses for maximum likelihood estimation of the ED50 for quantal dose-response data. Müller HG; Schmitt T Biometrics; 1990 Mar; 46(1):117-29. PubMed ID: 2350566 [TBL] [Abstract][Full Text] [Related]
18. A theory of drug tolerance and dependence I: a conceptual analysis. Peper A J Theor Biol; 2004 Aug; 229(4):477-90. PubMed ID: 15246785 [TBL] [Abstract][Full Text] [Related]
19. Role of baseline parameters in determining indirect pharmacodynamic responses. Sun YN; Jusko WJ J Pharm Sci; 1999 Oct; 88(10):987-90. PubMed ID: 10514344 [TBL] [Abstract][Full Text] [Related]
20. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects. Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]